Do healthtech startups need FDA clearance before raising a seed round?

Not necessarily — many digital health products fall outside FDA device regulation, but founders need to know definitively which category their product falls into and be able to explain it clearly.

How important is a peer-reviewed publication for a healthtech pitch?

Very helpful but not always required at early stages — a credible plan for generating clinical evidence, backed by pilot data, can be sufficient at seed, though the bar rises significantly at Series A and beyond.

Are healthtech sales cycles really as long as investors expect?

Often yes, particularly for products selling into health systems — being upfront and realistic about this builds more credibility than an optimistic projection that doesn't match the sector's real dynamics.

How does PitchProtocol help healthtech founders find the right investors?

PitchProtocol structures your reimbursement pathway, regulatory classification, and clinical evidence into a decision-ready package matched to funds with genuine healthtech diligence experience. Apply to the First 100 Founders Cohort →

How to Pitch VCs on a Healthtech Startup

What makes healthtech pitches different

Healthtech spans a wide range of business models — digital health software, medical devices, diagnostics, provider-facing tools, and consumer health apps — but nearly all of them intersect with regulation, clinical validation, or the healthcare payment system in ways that pure software companies don't. Investors with real healthtech experience evaluate pitches through this lens first, before getting to standard growth metrics.

Address reimbursement before anything else

State the reimbursement pathway explicitly. Whether a product is billed through existing CPT codes, requires a new code, is paid directly by employers or consumers, or depends on value-based care contracts changes the entire business model — investors want this addressed clearly and early, since an unclear reimbursement path is one of the most common reasons healthtech companies stall after early traction.

Show the sales cycle reality, not an optimistic version of it. Health system and payer sales cycles are often long and involve multiple stakeholders — investors who know the space will discount a growth projection that assumes an unrealistically fast enterprise health sales motion.

Address integration with clinical workflow directly. A product that requires meaningful behavior change from clinicians or adds friction to existing workflows faces real adoption headwinds — investors want evidence the company has thought through, and ideally tested, real-world workflow integration.

Regulatory classification and clinical evidence

Clarify FDA or regulatory status early and specifically. Whether a product is regulated as a medical device, falls under clinical decision support guidance, or sits outside FDA jurisdiction entirely changes the diligence conversation substantially — ambiguity here is treated as a red flag, not a detail to sort out later.

Bring real clinical evidence, not just user satisfaction data. For products making any clinical claim, investors expect data from real clinical validation — pilot studies, published outcomes data, or at minimum a credible plan for generating this evidence — rather than engagement metrics alone.

Address data privacy and security specifically (HIPAA and beyond). Healthtech companies handling protected health information face a higher security and compliance bar than typical software companies, and investors will ask pointed questions about this infrastructure.

What experienced healthtech investors ask

Specifics on the reimbursement code or payment mechanism, and evidence it's durable rather than a temporary workaround. The real sales cycle length based on actual deals closed, not an aspirational average. Clinical evidence that would hold up to a physician's scrutiny, not just a product team's internal metrics. And a clear regulatory classification with a credible path through it.

Skip the cold outreach. Submit one structured application and get matched to every relevant fund in the PitchProtocol network — pre-screened, pre-researched, and delivered directly to fund partners. Apply to the First 100 Founders Cohort →